The Skin Atelier, Inc., dba Skinprint, appears to have discontinued sales of OTC drug products on its website, along with Spot-On With 5% Micro-Benz Benzoyl Peroxide Spot Treatment, an unapproved new drug product that the FDA cited in a 1 October warning letter amid a host of GMP violations.

Maybe there’s truth in aloe, but there’s too little of it in earnings and health-related claims made by wellness and skin-care firm Aloe Vertitas and its Lifestyle Coaches, according to the direct-selling industry’s self-regulatory body. The DSSRC is referring the company to the Federal Trade Commission for failure to state its compliance or appellate intentions.

Essential oils no longer on list of products slated for EU tariff increases effective 18 October, a win for US fragrance industry facing uncertainty in tumultuous global trade climate. Fragrancy industry, like dietary supplement manufacturers, still face higher tariffs on imports from China as next round of hikes is scheduled to start 15 October.

Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.

The British independent ad regulator ruled on 9 October on a complaint regarding Neal’s Yard Remedies’ claims about promoting bee population health through charitable donations from its Bee Lovely product sales. Industry should be on notice that the ASA is actively fielding complaints about consumer-product companies’ environmental claims.

ASA says TV and radio ads for Ambre Solair Kids Sensitive Advanced sunscreens aired by Loreal Ltd. business implied that all of the brand's products on shelves met a 5-star rating system administered by Boots drug store chain and widely used in UK.

Approved by Governor Gavin Newsom 20 September, AB 647 requires chemical manufacturers to post material safety data sheets online in a readily accessible way and translate them into languages most prevalently spoken by salon workers.

The Safe Cosmetics and Personal Care Products Act, reintroduced in the US House, exceeds the proposed Personal Care Products Safety Act in the Senate in terms of the duties and resource demands it would impose on companies and the FDA, while leaving states free to regulate cosmetics even more stringently. The proposal now must vie for the attention of the Energy and Commerce Committee.

Funding issues appear to have factored in the proposed Cosmetic Fragrance and Flavor Ingredient Right to Know Act’s failure to cross the finish line in the first act of the California legislature’s 2019-2020 session. Far from popular with industry stakeholders, SB 574 nevertheless could represent a lesser-of-evils compromise of strategic importance, with further activity expected on the bill in 2020.

Market disruptions, “dramatically” higher prices, lost jobs and negative health consequences all are possible if legislation passed in New York in June to reduce 1,4-dioxane exposures is enacted in its current form, trade organizations say. Cleaning product industry advocates are leading the opposition, but personal-care manufacturers stand to be impacted as well.

Cosmetic cleansing products containing 1,4-dioxane at levels above 1 part per million would be unlawfully marketed in New York beginning in 2023 under legislation passed by the state’s legislature in June. Governor Andrew Cuomo reportedly is reviewing the bill.

Recall announcement doesn't mention litigation J&JU faces in multiple states alleging use of Johnson's Baby Powder causes cancer due from talc in formulation. But firm's sensitivity to consumer complaints or adverse event reports linked to brand is clear with talc-related litigation as backdrop.

Industry and the FDA agree that the OTC drug monograph system is direly in need of reform, but innovating with noncompliant dosage forms and indications, without approved new drug applications, is a risk companies need to weigh seriously, says Arnall Golden Gregory partner Alan Minsk. The FDA offers perspective on its OTC monographs for acne and antiperspirant products.

The Ninth Circuit will hear arguments from L’Oreal and a plaintiff who alleges the firm’s RevitaLift products are unlawfully marketed drugs, following the case’s dismissal in July on federal preemption grounds. In a neighboring California district, Beiersdorf intends to seek summary judgment in five-year-old litigation of a similar design, concerning Nivea Skin Firming Hydration Body Lotion.

The Miami Beach, FL-based company has dropped the “Organic” from its name but continues to go by Truly after at least four years of marketing skin-care and bath products as “certified organic” when in fact they were neither organic nor certified, according to the Federal Trade Commission.